ColorectalArchives
Tumour-Associated Neutrophils in Colorectal Cancer: a Systematic Review, Meta-analysis, and Comprehensive Literature Review
Colorectal 1 min.
Neutrophils are at the forefront of innate immune response. The prognostic impact of tumour-associated neutrophils (TANs) remains unclear. This study aimed to evaluate the prognostic role of TANs in colorectal cancer (CRC). Methods: A systematic review and meta-analysis were conducted using PubMed, Embase,...
Validation of the fear of cancer recurrence inventory-short form in long-term colorectal cancer survivors
Colorectal 1 min.
The Fear of Cancer Recurrence Inventory-Short Form (FCRI-SF) is commonly used to categorize the severity of fear of cancer recurrence (FCR) defined as fear, worry, or concern about cancer returning or progressing. Evaluating the FCRI-SF factor structure and the clinical cut-off score in specific cancer...
Fungi and colorectal cancer: from dysregulation to clinical translation
Colorectal 1 min.
Research on the gut microbiota has primarily focused on bacterial communities. However, the role of fungi-the second-largest eukaryotic component of the gut microbiome-in the development and progression of colorectal cancer (CRC) has been less extensively studied compared to bacteria. Recent studies...
Lipid metabolism as a central driver of immune remodeling and therapeutic vulnerability in metastatic colorectal cancer
Colorectal 1 min.
Dysregulated lipid metabolism has emerged as a defining hallmark of colorectal cancer (CRC) progression, particularly in metastatic disease, where metabolic adaptation and immune evasion are tightly interconnected, as demonstrated in both murine models and human studies. Increasing evidence has demonstrated...
Dexmedetomidine promotes colorectal cancer progression mediated by gamma-aminobutyric acid signaling
Colorectal 1 min.
Cancer cells exhibit abnormal dependence on glutamine, which is associated with the hyperactivation of γ-aminobutyric acid (GABA) metabolic pathways that promotes tumor growth. The α2-adrenergic receptor agonist dexmedetomidine (DEX) has been reported to promote colorectal cancers (CRC) progression....
